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Bronchial asthma is a costly disease and the correlated social impact is ever increasing. The
aim of the Social Impact of Respiratory Integrated Outcomes (SIRIO) study was to measure the
health resources consumption and the costs generated in 1 year by asthmatic patients
investigated in a real-life setting. This bottom–up, observational, prospective, multicentric
study was based on the collection of demographic, clinical, diagnostic, therapeutic and
outcome data of 577 patients with bronchial asthma who reported spontaneously to the
pneumology centers involved in the study. Of these, 485 patients (300 f, mean age 49.2
years716.3 S.D.) were eligible for analysis. At the baseline visit, the asthma severity was as
follows: 26.2% intermittent, 37.1% mild persistent, 29.5% moderate, and 6.6% severe. In the 12
months prior to enrollment, 243 patients (50.1%) had visited the general practitioner (GP); 349
(72%) consulted a National Health Service (NHS) specialist; 68 (14%) utilized Emergency Care;
and 50 (10.3%) had been admitted to hospital on account of asthma, with a total of 2059 work
days lost. At the end of the 1-year survey, asthma severity changed as follows: 32.8%
intermittent, 38.1% mild persistent, 23.7% moderate, and 4.3% severe, with a substantial drop
in corresponding outcomes: 39.6% visited their GP, 51.5% visited an NHS specialist, 5.2% used
Emergency Care, and 4.3% were admitted to hospital. Compared to baseline, the total average
cost per patient decreased globally by 17.9% (po0.001) after the 1-year survey. In conclusion,
during the study period we observed a signiﬁcant decline in health resources consumption and
thus in asthma cost of illness, even though speciﬁc costs for the pharmaceutical treatment of
asthma increased substantially. These results are likely due to a more strict control of patients
and to their more appropriate clinical management.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
o, Multidisciplinary and Rehabilitation Outpatient Clinic, Via Monsignor Cavigioli 10, 28021 Borgomanero,
22 869950.
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R.W. Dal Negro et al.2512Introduction Italy. The study was not designed to evaluate pharmaceu-Bronchial asthma is a costly disease and the correlated
social impact is ever increasing.1–5
The traditional health system based on ‘‘welfare’’ has
obliged health services in highly industrialized countries to
pay increasing attention to healthcare-generated costs; this
is largely due to the need to reconcile the limited economic
resources now available with the ever growing demand for
wellbeing coming from communities characterized by
increasingly longer life expectancy and expectation of a
higher standard of quality of life.
However, to be fully and effectively applicable, analyses
that estimate costs should be carried out in ‘‘real life’’
settings and not only based on experimental models that are
frequently unable to reproduce the behavioral components
affecting daily life decisions.6
Hence, the relevance of observational studies on health
outcomes is growing, since their aim is to provide data that
can be utilized for the improvement of health policies, to
reduce costs, and to consent a more rational distribution of
the available resources.1,6–8
The ﬁrst retrospective study carried out in Italy on the
socio-economic impact of asthma in adults dates back to
1992.9 Some time later, further data estimated the average
cost per asthmatic patient in Italy.10 According to these
data, the cost of illness was calculated at 0.2% of the gross
domestic product (GDP) for 1997, and the total direct health
cost of asthma represented 1.2% of the entire health budget
(1997) for Italy.10 Later studies conﬁrmed that in our country
the impact of asthma was high, both from the patients’
point of view and that of the society as a whole.9,11
In order to implement more effective management
strategies regarding bronchial asthma, a disease whose
epidemiology is currently undergoing rapid evolution, serial
studies are needed that allow to monitor, periodically and at
relatively short-term intervals, the impact of the disease as
precisely as possible. This in order to implement health
policy strategies oriented at controlling and reducing the
socio-economic burden of asthma. Moreover, the adoption of
prospective rather than retrospective models constitutes a
further step in achieving data which better approximate real
life behavioral trends.
The Social Impact of Respiratory Integrated Outcomes
(SIRIO) study represents a global outcome study aimed at
collecting and evaluating data related to the socio-econom-
ic impact of the major respiratory diseases (asthma, COPD,
community-acquired pneumonia (CAP)). The present paper
reports the ﬁndings with regard to bronchial asthma only.
Due to the strategic value of the initiative, SIRIO was
promoted by the Italian Pneumology Union (Unione Italiana
per la Pneumologia—UIP) and endorsed by the following
scientiﬁc societies: Associazione Italiana Pneumologi Ospe-
dalieri (Italian Association of Hospital Pneumologists—AIPO)
and Societa` Italiana Medicina Respiratoria (Italian Society of
Respiratory Medicine—SIMeR).Materials and methods
The SIRIO/asthma study consisted in the creation of an on-
line pharmacoeconomic network on bronchial asthma intical drugs, nor therapeutic strategies, nor diagnostic
procedures. It was only aimed to estimate economic cost
of bronchial asthma management in an Italian population
affected by this disease. The choice of a prospective design
allowed a greater precision in describing the different voices
for expenditure, the quality, speciﬁcity, and speed of data
calculation being optimized by the use of a dedicated
software for data collection and on-line analysis. This
bottom–up, observational, prospective, multicentric study
was based on the collection of demographic, clinical,
diagnostic, therapeutic, and outcome data of asthma
patients who spontaneously requested a pneumological
consultation.
Patient selection criteria
Patients were enrolled in the study if they fulﬁled the
following inclusion criteria: males or females of adult age
with a diagnosis of asthma according to the GINA 2001
guidelines12 in stable phase or symptomatic, who reported
spontaneously to the specialist center as a ﬁrst-time
patient, as a previous patient coming for a scheduled check,
or as a previous patient coming with symptoms of asthma
exacerbation. Asthma exacerbation was deﬁned as any
clinical asthma impairment requiring at least the increase
of previous asthma therapeutic regimen or a GP’s consulta-
tion. Patients’ inclusion in the study did not imply any
procedure, risk or advantage other than those of routine
clinical practice. All subjects gave their informed consent to
participate in the study and allowed the use of their
personal data for research purposes. Patients already
enrolled in clinical studies were excluded from the study.
Patient assessment
The study envisaged a minimum of two visits, one at
baseline and the other 1271 months later; if necessary,
further visits were possible during the 12-month survey. At
baseline, demographics (age, sex, marital status, and
employment situation), clinical data (asthma symptoms,
etiology, duration, and clinical severity of asthma, n.
exacerbations, presence of concomitant diseases), diagnos-
tic information (type and number of specialist/non-specia-
list examinations performed to assess asthma in the 12
months prior to enrollment), and management outcomes
(GP and specialist visits, recourse to Emergency Care,
hospital admissions, Day Hospital, work days off in the 12
months prior to enrollment, treatments prescribed) were
collected for each patient. The majority of patients who
spontaneously referred to the specialist centers had already
received their diagnosis of asthma. Nevertheless, diagnosis
was conﬁrmed in the recruited patients by collecting
anamnestic data, clinical information, and lung function
data. In many cases, GPs’ ﬁles were also consulted to clarify
particular situations, particularly concerning the number of
admissions or number of diagnostic tests carried out in the
12 months prior to enrollment.
As SIRIO was an observational study in real life, physicians
had the opportunity to prescribe the treatment they con-
sidered most suitable for their patients. Hence, no pre-set
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Costs of asthma in Italy 2513treatment was indicated to the physicians taking part in the
study, nor were any management indications recommended.
The only intervention was that, during the baseline visit,
patients were given the health status questionnaire EQ-5D
to self-complete,13 and the visual analog scale (VAS) to
assess their heath status.
The end-study visit was scheduled to take place at the end
of the follow-up period, i.e. 1271 months following recruit-
ment. If an unscheduled visit to the specialist center occurred
within this time frame, it could be used as the end-study visit.
Other visits that occurred close to the end-date of the study,
but outside the interval of 71 month allowed, were not
considered as end-study visits, and the patient was recalled for
a speciﬁc end-study visit, within the interval time established
by the protocol. If the patient could not be contacted, or
skipped, or had died in the interim period, the specialist
registered the information on the data collection card.
At the end-study visit, the same data collected during the
baseline visit were updated. As this visit was part of the
protocol, it was not considered in terms of resource
consumption. On the contrary, if a patient performed an
unscheduled visit to the center for any healthcare interven-
tion due to asthma, and if this occurred within the time frame
of the end-of-study visit (1271 months following recruit-
ment), that visit was calculated as additional healthcare
consumption, since it was not induced by the protocol but
spontaneously generated by an uncontrolled clinical change.
Data collection
Data were collected through a dedicated software that
encrypted patients’ names to guarantee anonymity; data
were sent via e-mail to a centralized database.
The questionnaire EQ-5D was given to the patient in paper
form; all questionnaires were then sent by mail to the
database center.
Study dimension
To ensure that data were representative of the whole of
Italy, Pneumological Centers were selected by the two
endorsing scientiﬁc societies according to strict geographi-
cal criteria for distribution; moreover, the modes of data
collection envisaged by the protocol made participation in
the study possible only for centers equipped with suitable
computer systems.
Preliminarily, by considering a possible variability of
150–200% in cost-of-illness, a patient sample of 1000–1500
subjects was calculated in order to accept a 10% error (with
95% conﬁdence interval). Moreover, considering a drop-out
percentage at follow-up of around 10–15%, each center
would have to recruit a total of approximately 50 patients,
variously distributed between asthma, COPD, and CAP.
In each center, patients were enrolled consecutively, i.e.
according to the order in which they presented to the
pneumologist for consultation.
Data analysis
Statistical comparisons were calculated by means of non-
parametrical tests (Welch test) in order to comparevariations in the most relevant outcomes (e.g. mean direct
and indirect costs, mean costs for each level of asthma
severity, mean total cost of illness) with respect to baseline,
and a po0.05 was considered as signiﬁcant.
Health costs
Health interventions (such as visits, diagnostic tests,
hospital admissions, etc.) were valued and the correspond-
ing real costs attributed.14–17 The following categories of
costs were considered.
Direct
These are the costs effectively generated by the respiratory
disease and/or sustained by patients. They include health
costs, such as the monetary value of the resources used for
diagnostic procedures and treatment (therapies, hospitali-
zation, etc.), and in general constitute an economic burden
prevalently borne by the NHS. Concomitant treatments,
such as any treatment needed to treat any co-morbidity
were also valued. Furthermore, the direct non-health costs
of different origin (e.g. transfers of patient and caregivers
for examinations and/or hospitalization, home care, etc.)
were calculated using average unitary costs of different
types, according to the case (transport tariffs, tariffs for
paid caregivers, etc.).
Indirect
These are costs which correspond to the loss of productivity
occurring as a result of a patient’s inability to work (or
death) on account of the disease. The economic burden of
indirect costs is mainly borne by the society.
To evaluate the indirect costs, we referred to the
patient’s current work activity, considering the mean daily
wage corresponding to such activity.
Intangible
These are costs not convertible in monetary terms, in that
they relate speciﬁcally to the distress and suffering caused
by the disease. Measurement of the patient’s self-percep-
tion of health status is performed by means of quantitative
scales. The perception of a poorer health status due to the
disease, compared to a conventional value indicating full
health, was considered as a proxy of the intangible costs.
Health status
Measurement of health status was performed by means of
the EQ-5D (Euro-Qol, Quality of Life in Europe) ﬁve-
dimension questionnaire in the ofﬁcial Italian version,13
which is a simple generic instrument of general applicability
to diseases and treatments. Patients identify their own
health status indicating on the ﬁrst page of the question-
naire which level of attitude (of the three given) best
corresponds to their situation for each of the ﬁve dimen-
sions: (1) movement capacity, (2) personal care, (3) habitual
activities, (4) pain or irritation and (5) anxiety and
depression. Each dimension has three response levels,
thus giving 243 possible health statuses. The information
gathered is synthesized by an algorithm in a score ranging
from 0 to 1.
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Table 1 Characteristics of study population.
No.(%)
Total 485
Mean age (years)(S.D.) 49.2(16.3)
Sex
Male 185(38.0)
Female 300(62.0)
Geographic distribution
Northern Italy 183(38.0)
Central Italy 120(25.0)
Southern Italy 182(38.0)
Occupational status
Full time employee 157(32.4)
Housewife 102(21.0)
Retired 102(21.0)
Self employed 49(10.1)
Student 41(8.5)
Unemployed 14(2.9)
Other 20(4.2)
Smoking habit
Non-smoker 240(64.2)
Smoker 47(13.0)
Ex-smoker 81(21.7)
N/A 6(1.6)
Respiratory therapy
Yes 457(94.0)
No 28(6.0)
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Figure 1 Distribution of patients according to clinical severity
(GINA guidelines 2001): (A) baseline, and (B) follow-up.
R.W. Dal Negro et al.2514Patients were required to grade their current perceived
health status on a VAS from 0 (‘‘worst health status
imaginable’’) to 100 (‘‘best health status imaginable’’).
As the instrument’s output is a single numerical value that
expresses the health-related quality of life, it can be used in
cost–utility analyses. Generally it takes just a few minutes
to complete the EQ-5D.
Ethical issues
The study was approved by the Ethics Committee of the
Coordinating Center which notiﬁed all participating centers.
Results
Of the 37 Pneumology Centers distributed throughout Italy
involved from the outset in the study, 28 of them enrolled
asthma subjects effectively. The nine centers which did not
recruit any subjects had severe bureaucratic delays with
their local ethical committees and missed the deadline for
entering the study; there was no particular geographic bias
in the distribution of these centers.
In the period November 2001–December 2003, 577 asthma
patients were enrolled, but only 485 (300 f, mean age
49.2 years716.3 S.D.) fully completed the 1-year survey
and thus were eligible for analysis (those patients who
spontaneously interrupted their participation, were never
seen, or whose forms were incompletely ﬁlled in were
considered ineligible). No patient died in the course of the
survey. The geographical distribution of the 485 patients
who underwent analysis is reported in Table 1. The two most
represented categories were housewives (33.7%) and full-
time employees (26.7%). The majority of patients had never
smoked.
In the vast majority of subjects, bronchial asthma had
previously been diagnosed and its mean duration was 13.7
years. At enrollment, the mean lung function (FEV1) values
in the four clusters of subjects with different asthma
severity according to GINA 2001 guidelines4 were as follows:
intermittent, 94.0%76.6 (mean FEV1 pred.7S.D.); mild
persistent, 86.4%75.2; moderate persistent, 70.1%75.6;
and severe persistent, 51.4%76.1. Their corresponding
distribution in the whole sample is reported in Figure 1A.
At the time of enrollment, almost all patients (95.9%)
with a previous diagnosis of asthma had already performed
at least one spirometry test, as compared to only 64% of
patients with a ﬁrst-time diagnosis of asthma. When both
categories of patients were combined, the mean time
interval since the last spirometry was on average 1.7 years.
Subjects already receiving invalidity pensions due to their
asthma were 2.7%. As regards exemption of payment for
disease, a total of 56.1% of subjects were already receiving
this beneﬁt, in particular 65.0% of patients with mild
asthma, 57.3% of those with moderate asthma, and 68.7%
of those with severe asthma.
One or more concomitant diseases were present in 53.8%
of patients, the most frequent being allergy-related (e.g.
rhinitis, conjunctivitis) together with cardiovascular dis-
eases (in particular, systemic arterial hypertension). Atopy
was present in 57.9% of patients, being perennial in 59.8%
and seasonal in 39.9% (Figure 2).Prior to enrollment, subjects had performed a total of
1913 diagnostic tests, in the following decreasing order of
frequency: simple spirometry (44.4%), standard chest X-ray
(12.2%), bronchodilatation test (11.8%), electrocardiogram
(9.8%), arterial blood gases analysis (8.7%), prick test (5.9%),
RAST (3.0%), and bronchial provocation test (2.8%). Many
other examinations were performed but all at a frequency
ARTICLE IN PRESS
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Figure 2 Distribution of concomitant diseases. Total number
of patients with at least one concomitant disease ¼ 261.
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Figure 3 Distribution of diagnostic tests carried out in the 12
months prior to enrollment.
Table 2 Exacerbations at baseline and at follow-up.
No. of
exacer-
bations
Baseline Follow-upy
No. of
patients
% No. of
patients
%
0 125 25.8 195 40.2
1–5 278 53.7 253 52.2
6–10 54 11.1 28 5.8
410 28 5.8 9 1.9
Total 485 100 485 100
In the 12 months preceding enrollment.
yDuring the course of the study (12 months).
Costs of asthma in Italy 2515lower than 1%. Their percentage distribution is reported in
Figure 3.
The incidence of asthma exacerbations as assessed in the
12 months prior to the study is reported in Table 2. Table 3
reports the absolute number and corresponding percentage
of patients who were visited by their GP or by an NHS
specialist, who utilized Emergency Care, or were hospita-
lized at least once, and the overall number of work days off
in the same period.
On average, the distance traveled by these patients to
reach the Specialist Center was 20.4 km, with a maximum of
89.8 km and minimum of 2.5 km in two centers, respectively,
in the south and north of Italy.
The mean initial value of EQ-5D was 0.795, that of the VAS
0.726: differences in scores due to age (over or under 64
years) were signiﬁcant (Table 4).At the end of the survey, the distribution of asthma
severity shifted globally towards the less severe levels, as
reported in Figure 1B. Also, the incidence of asthma
exacerbations diminished during the survey, showing a
substantial increase in non-exacerbating subjects and
corresponding decrease in frequent exacerbators; all ﬁgures
of these changes are reported in Table 2.
The number of visits by GP or an NHS pneumologist, or by
a private specialist, the use of Emergency Care, number of
hospital admissions, and number of work days off also
decreased substantially at the end of the survey (Table 3).
Also mean costs calculated at the end of the survey
dropped signiﬁcantly compared to baseline mean costs
(Table 5). In particular, both at baseline and end of the
survey, the mean total asthma cost could be seen to increase
in proportion to the asthma severity (Figure 4A and B).
No signiﬁcant differences were seen between males and
females in terms of the main outcomes.
Irrespective of the level of disease severity, the mean
total cost per patient also proved to be a direct function of
the number of exacerbations reported by the patient in the
period; in subjects who referred more than ﬁve exacerba-
tions per year, the cost proved more than double when
compared to that of subjects who did not report any
exacerbation (h2593.4973621.89 vs. h1211.8572071.03,
respectively, po0.01); Figure 5.
Despite the consistent and systematic reduction in both
direct and indirect costs calculated at the end of the survey,
the total cost still proved directly proportional to the
number of exacerbations reported by patients, those who
declared more than ﬁve exacerbations having produced the
highest total asthma cost (h2283.7173423.83 vs.
h900.057871.17, respectively; po0.01).
Concerning the treatment of patients, both at the time of
enrollment and at the end of the survey, 94% of the total
study population was in treatment for asthma (Table 1).
Moreover, in the 12 months prior to enrollment, respiratory
drugs accounted for 27.8% of the total asthma costs, while
those utilized for managing concomitant diseases corre-
sponded to 4.1% only. Costs related to other therapies
(homeopathy, etc.), or to environmental preventive treat-
ments or to medical procedures due the occurrence of
signiﬁcant side effects following main treatments were of an
absolutely marginal dimension (Table 5).
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Table 3 Recourse to visits and/or hospitalization and/or Emergency Care and work days lost by patients at (A) baseline, and
(B) follow-up.
Visits/admissions A (n ¼ 485) B (n ¼ 485)
n N No. of
patients
Percentage
of patients
n n No. of
patients
Percentage
of patients
Visits to GP 1405 243 50.1 644 192 39.6
NHS specialist visits 1037 349 72.0 518 250 51.5
Private specialist visits 80 39 8.0 48 27 5.6
Use of Emergency Care 120 68 14.0 64 25 5.2
Admissions 64 50 10.3 26 21 4.3
Day hospital 220 31 6.4 47 6 1.2
Total work days lost 2059 1198
Table 4 Health Questionnaire: EQ-5D and VAS scores for the total population and differentiated by age group.
No. of patients Score
Mean S.D. Min. Max.
EQ-5D 374 0.795 0.254 0.221 1.000
19–64 years 311 0.817 0.206 0.015 1.000
X65 years 63 0.686 0.275 0.221 1.000
VAS 374 0.726 0.183 0.000 1.000
19–64 years 311 0.738 0.183 0.000 1.000
X65 years 63 0.663 0.171 0.300 1.000
Normal references for Euroqual User Guide values: total, 0.856; subjecto65 years, 0.885; subject465 years, 0.740.
R.W. Dal Negro et al.2516At the end of the 1-year survey, a signiﬁcant increase in
drug costs was observed, mainly related speciﬁcally to
asthma therapy; this occurred without any further increase
in the percentage of subjects treated for asthma, which
remained as 94% of recruited subjects. In particular, at the
end of the survey, the incidence of use of inhaled steroids
did not change signiﬁcantly when compared to that
registered at baseline (404 vs. 394 subjects, respectively),
thus emphasizing that the mode of use (such as regular day
use, adhesion to prescriptions, etc.) likely changed sig-
niﬁcantly during the survey. Even though to a lesser extent,
also the cost for treating concomitant diseases increased in
the same period (Table 5). As mentioned above, the increase
in costs of basic asthma therapy was in any case accom-
panied by a marked, systematic decrease in all other direct
costs as well as in the indirect costs induced by the disease.
No signiﬁcant differences were seen in therapeutic
behavior between the three different macro-regions (north,
center, and south Italy) from which patients were recruited.Discussion
Bronchial asthma represents the respiratory disease that has
been most extensively investigated in economic
terms.1–4,18–21 In a society which is characterized byincreasingly limited resources, the need to optimize the
management of chronic pathological conditions otherwise
ungovernable from the socio-economic point of view has
become an urgent issue.
Useful information on the current effectiveness of asthma
management can be obtained from the integration of
epidemiological studies with pharmacoeconomic analyses,
which can be used for planning more effective interventions
in asthma management.
In our country, the conviction that bronchial asthma
should require more attention than in the past is just
beginning to dawn, and only in the last few years have
medical professionals and health policy decision makers
begun to take seriously into account the epidemiological and
social burden of asthma.
In USA in 1992, the annual cost of asthma was estimated
at approximately $6.2 billion,18 a ﬁgure which rose to more
than $12 billion in 1998,1 and has since continued to rise.19
Studies conducted in highly industrialized countries (USA,
UK, Sweden, Canada, Italy, Australia)18–20 have shown that
the cost of asthma constitutes a share of resources equal to
about 0.1–0.3% of the respective GDP. From these studies, it
has moreover emerged that about 50% of total asthma costs
is attributable to ‘‘indirect costs’’ (loss of productivity, early
retirement, invalidity, and sometimes, premature death).
Nevertheless, the share of ‘‘direct costs’’ (hospitalization,
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Table 5 Direct, indirect, and total mean costs per patient.
Parameters Baseline Follow-up
Mean cost per patient (n ¼ 485) Mean cost per patient (n ¼ 485)
Value (h) % Value (h) %
Principal pharmacological therapy 398.79 27.8 717.06 60.9
Concomitant pharmacological therapy 59.02 4.1 69.32 5.9
Admissions 348.47 24.3 122.07 10.4
Day hospital 113.41 7.9 24.55 2.1
Use of emergency care 5.11 0.4 2.75 0.2
Visits 112.26 7.8 56.75 4.8
Examinationsy 127.76 8.9 55.92 4.7
Speciﬁc immunotherapy 31.86 2.2 17.89 1.5
Veriﬁcations for side effects 0.30 0.0 0.09 0.0
Environmental preventive treatments and home
help
19.56 1.4 3.83 0.3
Alternative therapy 10.35 0.7 4.80 0.4
Total direct costs 1226.88 85.6 1075.01 91.3
Work absenteeism 207.14 14.4 102.39 8.7
Total indirect cost 207.14 14.4 102.39 8.7
Total costs 1434.0272227.53 100 1177.4071416.80yy 100
ySpirometry, blood gases analysis, skin allergy tests, ECG, chest X-ray IgE/Rast, bronchial provocation test, bronchodilatation test,
bronchoscopy, etc.
Visits to GP and specialist.
yypo0.015.
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Figure 4 Mean annual cost according to different degrees of asthma severity: (A) baseline, and (B) follow-up. The drop in costs
calculated for severe asthma after the 1-year survey was statistically signiﬁcant (po0.03). Costs proved equally related to severity
of asthma both at baseline and 1 year later (both ANOVA po0.01).
Costs of asthma in Italy 2517medical visits, specialist and non-specialist diagnostic tests,
pharmacological and non-pharmacological medical treat-
ment) remains signiﬁcant. This share of costs tends to vary
from country to country in virtue of the healthcare and
social welfare models in vigor, but also as a function of the
disease severity, general medical culture, and local socio-
health attitudes.20,21
Some pivotal studies had already highlighted the fact that
the use of respiratory treatments in persistent asthma is
often inadequate, with a consequent negative inﬂuence on
the control of asthma in real life both in adult and younger
asthmatics.22,23 Regardless of the goals of GINA guidelines, a
great proportion of asthma patients continue to reportdaytime symptoms of asthma, asthma-related sleep dis-
turbances, unscheduled medical visits, emergency room
visits, and overnight hospitalizations, thus conﬁrming that
the current asthma control is far from optimal with the
present long-term asthma management.22 Furthermore,
more than 50% of asthmatics persist in their asthmatic
symptoms and are under-treated, in the sense that their
drug daily use is much lower than what is indicated in the
present guidelines for the corresponding severity level of
their disease.23
In the last decade, some Italian studies aimed at
evaluating the costs related to bronchial asthma were
published; these studies unanimously conﬁrmed the high
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Figure 5 Regional distribution in Italy of mean total asthma
cost. No signiﬁcant difference was seen among the different
regions.
R.W. Dal Negro et al.2518impact of the disease, from the point of view of both the
patient and society.9,11,24,25
Generally speaking, the ﬁndings which emerge from the
SIRIO study conﬁrm the high and growing impact of asthma
in our country, and contribute to better deﬁning the
pharmacoeconomic issues and current situation in Italy of
the disease.
Bronchial asthma has today in Italy a prevalence of
around 6–7% in adults and of more than 11% in children;
corresponding costs are on average twice as much as they
were about a decade ago (as estimated in the ﬁrst studies
carried out), independently of the geographical region, and
atopic asthma still prevails (58.1%) over the non-atopic
form. Being a disease that strikes prevalently the most
productive age groups of the population, bronchial asthma
has obviously a large impact on the indirect costs, mainly
due to work and school absenteeism, i.e. that part of the
disease’s economic impact that constitutes a burden
essentially to society as a whole. On the other hand, and
different from other obstructive airways diseases, the
relatively young mean age of subjects suffering from asthma
leads to a lower impact of concomitant diseases affecting
organs other than the respiratory system. Regardlesss of
these aspects, bronchial asthma proves once again a disease
able to induce a signiﬁcant limitation in terms of quality of
life, particularly in subjects aged over 65 years.
The ﬁndings of the SIRIO study have shed further light on
how the current share of direct asthma costs (such as those
due to hospitalization, Emergency Care use, and consump-
tion of all other health goods and services) has become even
more prevalent and alarming compared to the recent past.3
These data also emphasize the still persisting basic asthma
under-treatment in Italy as a contributing factor of the
economic burden of the disease. As demonstrated in
previous studies,22,23 the treatment adherence tended to
improve during the survey with a consequent optimization of
the economic outcomes due to more strict patient control,
thus conﬁrming that the original asthma management was
far from optimal when SIRIO patients were recruited. From a
general point of view, this fact supports the hypothesis that
the current territorial health organization for the control of
bronchial asthma is still insufﬁcient and scarcely effective in
Italy. Data of the SIRIO study clearly emphasize that much
better outcomes could be obtained also in the economicsense through a simple, but long-lasting, specialist monitor-
ing of asthma patients.
Even though without any dramatic change in the basic
treatment options, it emerged that simply the specialist
care of patients proved sufﬁcient by itself to determine a
substantial reduction in healthcare expenditure, by low-
ering the impact of the most relevant outcomes, such as the
need for emergency interventions, unscheduled GP con-
sultations, etc., with a consequential decline in work
absenteeism. Actually, this optimization of outcomes could
be attributable purely to a more appropriate therapeutic
management of asthma. This is in complete agreement with
a previous suggestion that a change is needed from a
molecule-based approach to asthma to one in which the
focus is the patient as a whole, and in which the effects of
all asthma components are taken into account.26 On the
basis of the present ﬁndings, this conviction is proving strong
and mainly stems from the fact that, even in the presence of
an unchanged percentage of subjects treated for asthma,
economic and medical outcomes resulted optimized at
the end of the 1-year survey, regardless of the increase in
direct pharmacological costs. The optimization, then, would
correspond to a more appropriate use of the available
therapeutic tools.4
It is thus evident that if the principle of therapeutic
appropriateness loses its validity in general practice, a
broad range of asthmatic patients would not in fact have
access to those treatments which are commonly regarded as
most suitable for ensuring effective control of the disease.
These would represent circumstances in which, in case of
need, patients would have no option but to refer, with
varying frequency, to emergency structures or hospitals,
thus affecting negatively healthcare expenditures. More-
over, this once again conﬁrms that the appropriate use of
available therapeutic options does represent the corner-
stone of asthma management both in terms of effectiveness
and of efﬁciency.
The present study emphasized and quantiﬁed the eco-
nomic burden of asthma exacerbations, as events of
particular stress and risk for the patient, but also of
absolute negative signiﬁcance for the society as a whole,
due to their high economic impact.
Although to a lesser extent than in the recent past,9,10,27
patients with asthma still are poorly investigated and
monitored in our country; actually, it should be noted that
even though a large percentage of patients had already been
deﬁned as persistent asthmatic (but still were not ade-
quately controlled from a clinical point of view), the simple
procedure of spirometry had been performed in less than
40% of patients in the year prior to enrollment. Moreover,
considering that the share of asthma subjects with a ﬁrst-
time diagnosis was not negligible (about 20% of cases),
equally alarming was the fact that a reversibility test was
carried out in only about 10% of subjects, and a bronchial
provocation test in less than 3%. In other words, once again,
in real life, the picture of a substantial under-consideration
of asthma is conﬁrmed in our country; a further conﬁrmation
lies in the exceedingly low rate of recognition of the social
beneﬁts in favor of asthma patients, as only 50–60% of
patients were aware of and took advantage of exemptions.
Finally, optimization of outcomes and reduction in costs
were achieved through a more consistent use of therapeutic
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some previous studies, it would seem that a linear function
may relate the extent of therapeutic prescriptions (ob-
viously appropriate) and reduction in total asthma costs,
with a clear asymptotic trend.4,9–11,18,24,25 However, to
conﬁrm this particular hypothesis further ad hoc observa-
tional as well as economic studies on speciﬁc models are
required.
It is thus easy to understand the strong recommendations
for periodic analyses on the impact of bronchial asthma, in
order to implement optimal interventional strategies
against this disease characterized by a high variability and
ever increasing impact. If carried out with effective and
credible study models, these evaluations based on an
estimate of the resources consumption required for an
effective disease management represent an indispensable
tool that should guide decision makers in their future health
policies, both at local and at national level.
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